Microneedle Flu Vaccine Global Market Report 2025

The microneedle flu vaccine market size has grown rapidly in recent years. It will grow from $1.51 billion in 2024 to $1.67 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to the increasing global burden of seasonal influenza, rising awareness about the benefits of vaccination, government efforts to improve immunization coverage, a growing preference for minimally invasive drug delivery methods, and the early clinical success of microneedle vaccines in animal models.

The microneedle flu vaccine market size is expected to see rapid growth in the next few years. It will grow to $2.48 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The anticipated growth in the forecast period is driven by the expansion of pandemic preparedness initiatives, increasing preference for needle-free vaccination methods, broader application of microneedles for diseases beyond influenza, rising demand for patient-friendly vaccination options, and enhanced manufacturing scalability of microneedle patches. Key trends during this period include a shift toward dissolvable microneedle technologies, a growing focus on self-administered vaccine models, integration of microneedles with wearable health monitoring systems, a rise in clinical trials for microneedle-based influenza vaccines, and the adoption of microneedle platforms for pediatric and elderly populations.

The increasing prevalence of needle phobia is expected to drive the growth of the microneedle flu vaccine market. Needle phobia, also known as trypanophobia, is an intense fear or anxiety triggered by the sight, sensation, or anticipation of needle-based procedures, often leading individuals to avoid necessary medical interventions. This condition is primarily fueled by psychological sensitivity and negative past experiences, creating long-term fear and avoidance behavior. Microneedle flu vaccines provide a minimally invasive and nearly painless alternative, which reduces psychological barriers to vaccination and encourages better patient compliance. For example, in February 2025, the American Society for Clinical Pathology (ASCP) reported that approximately 50% to 60% of children experience needle phobia, with the fear being most prevalent between the ages of 4 and 6. As a result, the growing prevalence of needle phobia is contributing to the expansion of the microneedle flu vaccine market.

Leading companies in the microneedle flu vaccine market are focusing on securing investments to accelerate the development of patch-based RNA vaccines. These efforts support early-stage research and collaboration, advancing next-generation vaccine delivery technologies. For example, in March 2024, the Biomedical Advanced Research and Development Authority (BARDA), a U.S.-based government agency, announced a $50 million investment through the Patch Forward Prize to fast-track the development of microneedle patch-based RNA vaccines targeting influenza and COVID-19. This initiative aims to drive innovation by funding concept development and supporting the progression of combination products into Phase I clinical trials. The program fosters collaboration between vaccine developers and patch manufacturers, with the goal of overcoming technical and regulatory challenges, improving vaccine accessibility, and bolstering national preparedness for infectious diseases.

In January 2024, Gylden Pharma Limited (formerly Emergex Vaccines Holding Limited), a UK-based clinical-stage biotechnology company, partnered with DEKA Research & Development Corp. to enhance patient-friendly drug delivery through advanced microneedle-based intradermal administration technologies. The collaboration seeks to evaluate the compatibility and effectiveness of combining Emergex’s immunotherapeutic candidates with DEKA’s microneedle applicator for potential clinical use. DEKA Research & Development Corp., a U.S.-based company specializing in microneedle solutions, will play a pivotal role in advancing this technology.

Major players in the microneedle flu vaccine market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Novartis AG, Becton Dickinson and Company (BD), AptarGroup, Corium International, CosMED Pharmaceutical Co. Ltd., Vaxxas, PharmaJet, Inovio Pharmaceuticals, Vaxess Technologies, FluGen Inc., Debiotech S.A., Micron Biomedical Inc., NanoPass Technologies Limited, Micropoint Technologies Pte Ltd., TSRL Inc., Verndari Inc., and Microdermics Inc.

North America was the largest region in the microneedle flu vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in microneedle flu vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the microneedle flu vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The microneedle flu vaccine is an innovative vaccination method that uses a small, patch-like array of microscopic needles to painlessly deliver the influenza vaccine into the skin. This approach offers a minimally invasive, efficient, and user-friendly alternative to traditional intramuscular injections. It is designed to enhance vaccine accessibility, increase patient compliance, facilitate self-administration, and improve immunization coverage, especially in large-scale public health initiatives.

The main product types of microneedle flu vaccines include hollow microneedles, solid microneedles, coated microneedles, and dissolving microneedles. A hollow microneedle is a micro-scale needle with a central lumen, allowing for the direct injection of liquid formulations into the skin. These vaccines can be administered through various routes, such as oral, parenteral, and nasal, and are distributed through several channels, including hospital pharmacies, retail pharmacies, and online pharmacies. Applications for these vaccines include flu vaccination, seasonal flu prevention, pediatric vaccines, and vaccines for the elderly.

The microneedle flu vaccine market research report is one of a series of new reports that provides microneedle flu vaccine market statistics, including microneedle flu vaccine industry global market size, regional shares, competitors with a microneedle flu vaccine market share, detailed microneedle flu vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the microneedle flu vaccine industry. This microneedle flu vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The microneedle flu vaccine market consists of sales of polymer-based microneedle patches, hydrogel-forming microneedles, silicon microneedle arrays, biodegradable microneedle systems, metallic microneedles, and lipid-based microneedle formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.